Document Detail


Newer insulin analogs: advances in basal insulin replacement.
MedLine Citation:
PMID:  23448197     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Basal insulin analog therapy is the most common method of introducing insulin replacement therapy for the majority of patients with type 2 diabetes mellitus. Long-acting insulin analogs provide relatively peakless and more physiologic insulin replacement therapy than neutral protaminated Hagedorn insulin. Recently 2 new basal insulin analogs have been developed with superior pharmacokinetic and pharmacodynamics properties; insulin degludec and a pegylated insulin lispro. These agents are generally well tolerated and have been evaluated in both type 1 and type 2 diabetes. In this article we review the results of clinical trials assessing the efficacy, safety and tolerability of these newer longer-acting insulin analogs. In general rates of hypoglycaemia in these trials were low, glucose control was comparable to currently available basal insulin analogs, and rates of nocturnal hypoglycaemia were significantly and substantially lower. While further study will be required, advances in basal insulin replacement may offer important advantages over existing options for starting insulin strategies.
Authors:
Bernard Zinman
Related Documents :
24187547 - Perspective: a systems approach to diabetes research.
24278227 - Impact of glucose-lowering agents on the risk of cancer in type 2 diabetic patients. th...
24625937 - Diabetic peripheral neuropathy and its evaluation in a clinical scenario: a review.
24300017 - Diabetes in the middle-east and north africa: an update for 2013 for the idf diabetes a...
3618627 - Metabolic effects of fructose as a natural sweetener in the physiologic meals of ambula...
22688337 - Postprandial platelet activation is related to postprandial plasma insulin rather than ...
Publication Detail:
Type:  JOURNAL ARTICLE    
Journal Detail:
Title:  Diabetes, obesity & metabolism     Volume:  15     ISSN:  1463-1326     ISO Abbreviation:  Diabetes Obes Metab     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-3-1     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100883645     Medline TA:  Diabetes Obes Metab     Country:  -    
Other Details:
Languages:  ENG     Pagination:  6-10     Citation Subset:  -    
Copyright Information:
© 2013 Blackwell Publishing Ltd.
Affiliation:
Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada; Leadership Sinai Centre for Diabetes, Toronto, Ontario, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The need for better insulin therapy.
Next Document:  Methods to enhance delivery of prandial insulin and basal-prandial insulin.